1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,056 | 4,288 | 13:09 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GENFLEET THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| Fr | GENFLEET-B (02595): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| Fr | GENFLEET-B (02595): COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| Mi | GENFLEET-B Places Shares at Nearly 10% Discount, Expected Net Proceeds Exceed HKD467 Million | 1 | AASTOCKS | ||
| Mi | GENFLEET-B (02595): PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 29.06. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT PROPOSED SHARE REPURCHASE ON THE MARKET | 2 | HKEx | ||
| 02.06. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 MONOTHERAPY DATA PRESENTED AT 2026 ASCO ORAL SESSION: WORLD'S FIRST DEDICATED DATA OF A RAS INHIBITOR ... | 1 | HKEx | ||
| 01.06. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT PRELIMINARY PHASE I DATA OF GFS202A FOR CACHEXIA PRESENTED IN POSTER SESSION OF 2026 ASCO ANNUAL MEETING, FEATURING ... | 1 | HKEx | ||
| 11.05. | GENFLEET-B (02595): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 11, 2026 | 1 | HKEx | ||
| 28.04. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT STATEMENT ON THE PROPRIETARY INTELLECTUAL PROPERTY STATUS OF GFH276, A PAN RAS (ON) INHIBITOR | 1 | HKEx | ||
| 17.04. | GENFLEET-B (02595): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, 11 MAY 2026 | 1 | HKEx | ||
| 17.04. | GENFLEET-B (02595): NOTICE OF THE 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 17.04. | GENFLEET-B (02595): CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| 17.04. | GENFLEET-B (02595): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 09.04. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 GRANTED WITH SECOND BREAKTHROUGH THERAPY DESIGNATION, AS THE FIRST KRAS G12D INHIBITOR MONOTHERAPY INCLUDED ... | 1 | HKEx | ||
| 25.03. | GENFLEET-B (02595): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 2 | HKEx | ||
| 25.03. | GENFLEET-B (02595): TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 25.03. | GENFLEET-B (02595): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | 3 | HKEx | ||
| 25.03. | GENFLEET-B (02595): (1) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025; (2) CHANGE OF THE JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE ... | 1 | HKEx | ||
| 20.03. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT PRECLINICAL RESEARCH DATA OF THREE LARGE- AND SMALL-MOLECULE TARGETED THERAPIES RELEVANT TO RAS PATHWAY TO ... | 1 | HKEx |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 70,19 | 0,00 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,300 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,12 | -0,02 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ERASCA | 18,810 | -0,05 % | Erasca closes $632.5 million public stock offering | ||
| TARSUS PHARMACEUTICALS | 56,33 | +0,14 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth | IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,455 | +0,02 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,310 | -0,08 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TREVI THERAPEUTICS | 16,765 | -0,03 % | BMO initiates Trevi Therapeutics stock at Outperform, $36 target | ||
| HEMAB THERAPEUTICS | 49,390 | 0,00 % | Hemab präsentiert Phase-2-Daten für Sutacimig und plant Phase-3-Studie | ||
| KYMERA THERAPEUTICS | 111,11 | +0,04 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 304,26 | -0,06 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| QIAGEN | 35,055 | -2,68 % | BERENBERG stuft QIAGEN NV auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 50 auf 40 Euro gesenkt und die Aktien von "Buy" auf "Hold" abgestuft. Analyst Harry Gillis rechnet mit zunehmendem... ► Artikel lesen | |
| IMMIX BIOPHARMA | 8,800 | 0,00 % | Kehoe Law Firm, P.C.: Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims | Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Immix Biopharma, Inc. ("Immix Biopharma")... ► Artikel lesen | |
| VOR BIOPHARMA | 17,450 | 0,00 % | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,230 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen |
Das Unternehmen GENFLEET THERAPEUTICS SHANGHAI INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,04 % bei einem Aktienkurs von 4,076 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLEET THERAPEUTICS SHANGHAI INC finden Sie auf Wallstreet Online.